Dominik Schumacher, Tubulis CEO
German ADC biotech Tubulis raises $138M to enter the clinic and expand in US
Munich-based Tubulis has brought in prominent European and US investors to back its work in antibody-drug conjugates, which have taken oncology R&D by storm.
The biotech raised $138.8 million in what it called a Series B2. The round gives Tubulis the financial flexibility to be open about its next steps, including the potential for an IPO in the US, co-founder and CEO Dominik Schumacher said in an interview with Endpoints News.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
